ZeroStack (ZSTK) Aktienübersicht
Die ZeroStack Corp. ist über ihre Tochtergesellschaft, die Phatebo GmbH, im Bereich des Arzneimittelvertriebs in Deutschland tätig. Mehr Details
| Schneeflocken-Punktzahl | |
|---|---|
| Bewertung | 2/6 |
| Künftiges Wachstum | 0/6 |
| Vergangene Leistung | 0/6 |
| Finanzielle Gesundheit | 3/6 |
| Dividenden | 0/6 |
ZSTK Community Fair Values
Create NarrativeSee what 8 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
ZeroStack Corp. Wettbewerber
Preisentwicklung & Leistung
| Historische Aktienkurse | |
|---|---|
| Aktueller Aktienkurs | US$4.28 |
| 52-Wochen-Hoch | US$47.00 |
| 52-Wochen-Tief | US$3.72 |
| Beta | 1.86 |
| 1 Monat Veränderung | -42.92% |
| 3 Monate Veränderung | -48.56% |
| 1 Jahr Veränderung | -84.39% |
| 3 Jahre Veränderung | -97.80% |
| 5 Jahre Veränderung | -99.86% |
| Veränderung seit IPO | -99.89% |
Aktuelle Nachrichten und Updates
ZSTK: Forward Share Split Authorization Will Drive Future Upside Potential
Analysts have adjusted their price target on ZeroStack to $11.00. The change reflects updated views on discount rates and profit margin expectations, while fair value and future P/E assumptions remain steady.ZSTK: Forward Share Split Authorization Will Support Future Upside Potential
Analysts have raised their price target on ZeroStack to $11.00, citing a slightly higher profit margin outlook and a lower discount rate in their updated valuation work. What's in the News Flora Growth Corp.Recent updates
ZSTK: Forward Share Split Authorization Will Drive Future Upside Potential
Analysts have adjusted their price target on ZeroStack to $11.00. The change reflects updated views on discount rates and profit margin expectations, while fair value and future P/E assumptions remain steady.ZSTK: Forward Share Split Authorization Will Support Future Upside Potential
Analysts have raised their price target on ZeroStack to $11.00, citing a slightly higher profit margin outlook and a lower discount rate in their updated valuation work. What's in the News Flora Growth Corp.FLGC: Forward Share Split Authorization Will Support Future Upside Potential
Analysts have reduced their fair value estimate for Flora Growth from $20.50 to $11.00, citing updated assumptions that now reflect a steeper projected revenue decline of 24.87% along with a slightly lower discount rate and essentially unchanged profit margin and future P/E inputs. What's in the News Shareholders approved giving the board authority to change the company name to ZeroStack Corp.Flora Growth Corp. (NASDAQ:FLGC) Looks Inexpensive After Falling 26% But Perhaps Not Attractive Enough
To the annoyance of some shareholders, Flora Growth Corp. ( NASDAQ:FLGC ) shares are down a considerable 26% in the...FLGC: Forward Share Split And Preferred Share Authorization Will Drive Upside
Analysts now place their price target for Flora Growth at US$20.50, unchanged from the prior US$20.50. They cite only marginal tweaks to inputs, such as a slightly lower discount rate, while keeping revenue growth and profit margin expectations effectively stable.FLGC: Forward Share Split And Preferred Shares Will Support Upside Potential
Analysts have modestly raised their price target on Flora Growth, increasing the estimate by $0.00 to reflect a slightly higher perceived risk profile driven by an uptick in the discount rate, while keeping long term growth and profitability expectations essentially unchanged. What's in the News Shareholders approved giving the board authority to change the company name to ZeroStack Corp., create a new class of preferred shares, and implement a forward share split of between 2:1 and 10:1.FLGC: Forward Share Split And New Capital Raising Will Fuel Upside Potential
Analysts have modestly raised their price target on Flora Growth to $20.50, citing a slightly lower perceived risk reflected in a reduced discount rate, while maintaining stable expectations for revenue growth and profit margins. What's in the News Flora Growth has convened a special shareholders meeting for December 19, 2025 in Toronto to vote on corporate actions including capital structure and governance items (company filing).FLGC: Forward Share Split and Equity Offering Will Drive Renewed Momentum
Analysts have significantly lowered their price target for Flora Growth from $93.00 to $20.50. They cite revised expectations for revenue growth and a slightly reduced discount rate as key factors influencing this adjustment.Flora Growth Corp.'s (NASDAQ:FLGC) Shares Leap 26% Yet They're Still Not Telling The Full Story
Flora Growth Corp. ( NASDAQ:FLGC ) shareholders are no doubt pleased to see that the share price has bounced 26% in the...US Cannabis And European Beverage Markets Will Create Opportunities
Flora Growth’s consensus Analyst Price Target was notably reduced from $156.00 to $93.00 due to continued gross margin pressure, underwhelming operational progress despite a strategic shift toward branded U.S. and European opportunities, and softer-than-expected recent results, although long-term confidence in management’s direction remains. Analyst Commentary Gross margin pressure negatively impacted Flora Growth's bottom line results this quarter.Investors Aren't Buying Flora Growth Corp.'s (NASDAQ:FLGC) Revenues
Flora Growth Corp.'s ( NASDAQ:FLGC ) price-to-sales (or "P/S") ratio of 0.3x might make it look like a buy right now...
US Cannabis And European Beverage Markets Will Create Opportunities
Regulatory changes and strategic U.S. expansion could significantly enhance Flora's presence and revenue growth in the cannabis industry.Is Flora Growth (NASDAQ:FLGC) Using Too Much Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Flora Growth Corp. (NASDAQ:FLGC) Might Not Be As Mispriced As It Looks After Plunging 25%
To the annoyance of some shareholders, Flora Growth Corp. ( NASDAQ:FLGC ) shares are down a considerable 25% in the...Flora Growth Corp.'s (NASDAQ:FLGC) Price Is Right But Growth Is Lacking After Shares Rocket 28%
Flora Growth Corp. ( NASDAQ:FLGC ) shares have continued their recent momentum with a 28% gain in the last month alone...Health Check: How Prudently Does Flora Growth (NASDAQ:FLGC) Use Debt?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...The Market Lifts Flora Growth Corp. (NASDAQ:FLGC) Shares 26% But It Can Do More
Flora Growth Corp. ( NASDAQ:FLGC ) shareholders would be excited to see that the share price has had a great month...Newsflash: Flora Growth Corp. (NASDAQ:FLGC) Analysts Have Been Trimming Their Revenue Forecasts
Today is shaping up negative for Flora Growth Corp. ( NASDAQ:FLGC ) shareholders, with the analysts delivering a...Slammed 27% Flora Growth Corp. (NASDAQ:FLGC) Screens Well Here But There Might Be A Catch
The Flora Growth Corp. ( NASDAQ:FLGC ) share price has softened a substantial 27% over the previous 30 days, handing...Flora Growth Corp.'s (NASDAQ:FLGC) Shares Leap 143% Yet They're Still Not Telling The Full Story
Flora Growth Corp. ( NASDAQ:FLGC ) shareholders would be excited to see that the share price has had a great month...Investors Don't See Light At End Of Flora Growth Corp.'s (NASDAQ:FLGC) Tunnel And Push Stock Down 51%
The Flora Growth Corp. ( NASDAQ:FLGC ) share price has softened a substantial 51% over the previous 30 days, handing...The Market Lifts Flora Growth Corp. (NASDAQ:FLGC) Shares 41% But It Can Do More
Flora Growth Corp. ( NASDAQ:FLGC ) shares have had a really impressive month, gaining 41% after a shaky period...Investors Give Flora Growth Corp. (NASDAQ:FLGC) Shares A 28% Hiding
Flora Growth Corp. ( NASDAQ:FLGC ) shares have retraced a considerable 28% in the last month, reversing a fair amount...News Flash: Analysts Just Made A Meaningful Upgrade To Their Flora Growth Corp. (NASDAQ:FLGC) Forecasts
Flora Growth Corp. ( NASDAQ:FLGC ) shareholders will have a reason to smile today, with the analysts making substantial...Aktionärsrenditen
| ZSTK | US Healthcare | US Markt | |
|---|---|---|---|
| 7D | 2.3% | -2.8% | -0.8% |
| 1Y | -84.4% | 14.6% | 27.1% |
Rendite im Vergleich zur Industrie: ZSTK unter dem Niveau der Branche US Healthcare , die im vergangenen Jahr eine Rendite von 14.6% erzielte.
Rendite vs. Markt: ZSTK hinter dem Markt US zurück, der im vergangenen Jahr eine Rendite von 27.1 erzielte.
Preisvolatilität
| ZSTK volatility | |
|---|---|
| ZSTK Average Weekly Movement | 17.7% |
| Healthcare Industry Average Movement | 7.5% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.2% |
Stabiler Aktienkurs: Der Aktienkurs von ZSTK war in den letzten 3 Monaten im Vergleich zum US -Markt volatil.
Volatilität im Zeitverlauf: ZSTKDie wöchentliche Volatilität (18%) war im vergangenen Jahr stabil, liegt aber immer noch höher als bei 75 % der US Aktien.
Über das Unternehmen
| Gegründet | Mitarbeiter | CEO | Website |
|---|---|---|---|
| 2019 | 21 | Daniel Reis-Faria | zerostack.ai |
Die ZeroStack Corp. ist über ihre Tochtergesellschaft Phatebo GmbH in Deutschland im Bereich des Arzneimittelvertriebs tätig. Das Unternehmen ist in den Segmenten Commercial & Wholesale und Digital Assets tätig. Das Unternehmen vertreibt eine Reihe von pharmazeutischen Gütern und medizinischen Produkten zur Behandlung verschiedener gesundheitlicher Indikationen, darunter Medikamente für Krebstherapien, Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung, Multiple Sklerose und Antidepressiva.
ZeroStack Corp.'s Grundlagenzusammenfassung
| ZSTK grundlegende Statistiken | |
|---|---|
| Marktanteil | US$10.43m |
| Gewinn(TTM) | -US$151.73m |
| Umsatz(TTM) | US$36.08m |
Ist ZSTK zu teuer?
Siehe Fair Value und BewertungsanalyseErträge & Einnahmen
| ZSTK Gewinn- und Verlustrechnung (TTM) | |
|---|---|
| Einnahmen | US$36.08m |
| Kosten der Einnahmen | US$31.82m |
| Bruttogewinn | US$4.26m |
| Sonstige Ausgaben | US$155.99m |
| Gewinn | -US$151.73m |
Zuletzt gemeldete Gewinne
Mar 31, 2026
Datum des nächsten Gewinnberichts
k.A.
| Gewinn per Aktie (EPS) | -62.43 |
| Bruttomarge | 11.81% |
| Nettogewinnspanne | -420.49% |
| Schulden/Eigenkapital-Verhältnis | 8.6% |
Wie hat sich ZSTK auf lange Sicht entwickelt?
Historische Performance und VergleicheUnternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/05/22 22:23 |
| Aktienkurs zum Tagesende | 2026/05/22 00:00 |
| Gewinne | 2026/03/31 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
ZeroStack Corp. wird von 2 Analysten beobachtet. 0 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Rommel Dionisio | Aegis Capital Corporation |
| William Kirk | Roth Capital Partners |